Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia boosts animal rights with new guidance for researchers

This article was originally published in Clinica

Executive Summary

Australia has boosted its regulations governing animal rights in scientific research. A new guideline has been released, which is described as “in line” with the current “Code of Practice for the Care and Use of Animals for Scientific Purposes”, which is a mandatory monitored standard for all research institutions in the country. The guidance, which has attracted international interest and will be circulated to research bodies in the UK, Asia and Europe, reportedly focuses on “all aspects of the care of animals used in research”, through reference to the “3 Rs”: replacement of animals with other research methods; reduction of the number of animals used in research; and refinement of research techniques to minimise pain and distress. “The Guidelines to Promote the Wellbeing of Animals Used for Scientific Purposes: The Assessment and Alleviation of Pain and Distress in Research Animals” was released by the National Health and Medical Research Council (NHMRC) in August. The guidance was developed by animal care experts, researchers and Animal Welfare Committee members on behalf of the NHMRC. The guidelines are available from the NHMRC website.

You may also be interested in...

Asia Regulatory Forum Update

Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.

Saudi Arabia adopts interim device authorisation regulation

Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.

Canada takes action to increase more adverse event reporting

The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts